Journal
NEUROBIOLOGY OF DISEASE
Volume 32, Issue 1, Pages 16-25Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2008.06.003
Keywords
autophagy; lactacystin; Parkinson's disease; rapamycin; ubiquitin-proteasome system
Categories
Funding
- Diana Helis Henry Medical Research Foundation
- NIH [NS 043567, NS 40370]
- National Parkinson Foundation
Ask authors/readers for more resources
The ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP) are the two most important cellular mechanisms for protein degradation. To investigate the role of autophagy in reversing neuronal injury, the proteasome inhibitor lactacystin Was used to Cause UPS dysfunction in differentiated PC12 cells and in C57BL/6 mice and rapamycin Was used as an autophagy enhancer. The results showed that rapamycin pre-treatment attenuated lactacystin-induced apoptosis and reduced lactacystin-induced ubiquitinated protein aggregation in differentiated PC12 cells. The observed protection was partially blocked by the autophagy inhibitor 3-methyladenine. Furthermore, post-treatment of mice with rapamycin significantly attenuated lactacystin-induced loss of nigral DA neurons and the reduction of striatal DA levels. The lactacystin-induced high molecular ubiquitinated proteins were also attenuated by rapamycin treatment in vivo. In addition, as a chemical compound, rapamycin caused an increase of bc12 protein level and blocked the release of cytochrome c from mitochondria to cytosal. We concluded that the neuroprotective effect of rapamycin is partially mediated by autophagy enhancement through enhanced degradation of misfolded proteins and autophagy enhancement may be considered to be a promising Strategy to prevent diseases associated with misfolded/aggregated proteins, Such as Parkinson's disease. (C) 2008 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available